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INTRODUCTION
Duchenne muscular dystrophy (DMD) is one of the most common 
and severe inherited neuromuscular disorders, affecting 1  in 3,500 
newborn males. DMD is caused by mutations in the dystrophin gene 
encoding a key structural protein of the dystrophin glycoprotein 
complex, which connects the contracting cytoskeletal machinery of 
skeletal and cardiac muscle fibers to the extracellular matrix scaffold.1 
The absence of dystrophin in DMD patients causes a broad spectrum 
of physical consequences, eventually leading to a premature death.2 
Approximately 20% of deaths are the result of cardiomyopathies 
and/or cardiac conduction abnormalities. The improvement in treat-
ments of respiratory muscle disease allowed an increased life span 
of patients affected by DMD. Consequently, cardiomyopathies (which 
are present in ~90% of DMD patients) are emerging as a major cause 
of morbidity and mortality.3 In addition, many experimental therapies 
have mainly focused on skeletal muscle, aiming at the restoration of 
dystrophin expression in myofibers, and have failed to improve car-
diac function.4
The derivation of DMD patient–specific cardiomyocytes (CMs) 
and the correction of their genetic defect could provide a valuable 
cell source for in vitro modeling and for studying DMD-related car-
diac dysfunctions, in addition to potentially representing a signifi-
cant advancement toward an effective therapy for DMD-associated 
cardiomyopathies.
The efficient reprogramming technology pioneered by 
Yamanaka and colleagues5 opened the perspective of deriving 
large numbers of disease-specific human cells in vitro. Human 
induced pluripotent stem (hiPS) cells are recently emerging as an 
ideal cell source for the generation of clinically relevant cardiac dis-
ease models.6 Several recent studies demonstrate how hiPS cell–
derived CMs can be used for modeling the pathological phenotype 
of inherited cardiac disorders, such as the LEOPARD syndrome,7 
type 1 and 2 long QT  syndrome,8–10 catecholaminergic polymorphic 
ventricular tachycardia,11 arrhythmogenic right ventricular dyspla-
sia/cardiomyopathy,12 and the dilated cardiomyopathy.13 However, 
to our knowledge, CMs from DMD patient–derived hiPS cells have 
never been obtained so far.
Disease-specific hiPS cell–derived CMs could represent a platform 
for studying in vitro the pathological dystrophic phenotype and for 
testing and validating the therapeutic approaches and their effi-
ciency in restoring the normal phenotype.14 In addition, it has been 
recently demonstrated that hiPS cell–derived CMs can efficiently 
integrate in injured hearts of a guinea pig,15 providing a proof of 
principle for the application of these cells in regenerative medicine 
aiming at the treatment of cardiac dysfunctions.
In the perspective of a therapeutic application, the genetic defect 
of CMs derived from inherited disease–specific hiPS cells should be 
corrected before these cells are reengrafted in the patient.
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Duchenne muscular dystrophy (DMD)–associated cardiac diseases are emerging as a major cause of morbidity and mortality in DMD 
patients, and many therapies for treatment of skeletal muscle failed to improve cardiac function. The reprogramming of patients’ 
somatic cells into pluripotent stem cells, combined with technologies for correcting the genetic defect, possesses great potential 
for the development of new treatments for genetic diseases. In this study, we obtained human cardiomyocytes from DMD patient–
derived, induced pluripotent stem cells genetically corrected with a human artificial chromosome carrying the whole dystrophin 
genomic sequence. Stimulation by cytokines was combined with cell culturing on hydrogel with physiological stiffness, allowing an 
adhesion-dependent maturation and a proper dystrophin expression. The obtained cardiomyocytes showed remarkable sarcomeric 
organization of cardiac troponin T and α-actinin, expressed cardiac-specific markers, and displayed electrically induced calcium tran-
sients lasting less than 1 second. We demonstrated that the human artificial chromosome carrying the whole dystrophin genomic 
sequence is stably maintained throughout the cardiac differentiation process and that multiple promoters of the dystrophin gene 
are properly activated, driving expression of different isoforms. These dystrophic cardiomyocytes can be a valuable source for in vitro 
modeling of DMD-associated cardiac disease. Furthermore, the derivation of genetically corrected, patient- specific cardiomyocytes 
represents a step toward the development of innovative cell and gene therapy approaches for DMD.
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DMD is among the most difficult genetic diseases to treat, and the 
dystrophin gene is the largest gene described in the human genome. 
Promising results have been obtained in rodent models of Duchenne 
cardiomyopathy using adeno-associated viruses carrying minimized 
synthetic dystrophin genes (mini- and microdystrophin).16 These 
approaches do not allow the insertion of a complete functional 
version of the dystrophin gene. On the other hand, exon-skipping 
approaches,17 which redirect the gene processing bypassing the 
mutation, can be applied only to defined ranges of patients, based 
on their specific mutations. Several studies suggest that utrophin 
may help in the preservation of heart function in young adult mdx 
mice and heterozygous mdx mice.18,19 However, similar to dystro-
phin, the large size of the utrophin gene also presents a significant 
challenge to gene delivery.16 Other approaches for the treatment of 
Duchenne cardiomyopathy include the forced expression of sarco-
endoplasmic reticulum calcium-ATPase via adeno-associated virus 
gene transfer, aimed at restoring calcium homeostasis and improv-
ing cardiac contractility,20 without correction of the genetic defect.
A highly promising gene delivery tool for the correction of the 
DMD gene is represented by human artificial chromosomes (HACs). 
HAC is an artificially created exogenous minichromosome hav-
ing the ability to replicate and segregate autonomously in target 
human cells and to be stably maintained at episomal level, without 
integration into the host genome. In addition, HACs have the capac-
ity to carry large genomic loci with all their regulatory elements.21
An HAC vector carrying, for the first time, the whole dystrophin 
genomic locus including the associated regulatory elements (DYS-
HAC) was developed by Hoshiya et al.22 Furthermore, Kazuki et al.23 
have demonstrated the complete correction of hiPS cells derived 
from a DMD patient, using the DYS-HAC, pioneering an innovative 
and promising therapeutic approach for the treatment of DMD and 
DMD-associated cardiac diseases.
The first preclinical proof of safety and efficacy of DYS-HAC–
mediated therapy has been provided by Tedesco et al.24 In this 
study, the authors showed a significantly ameliorated phenotype in 
the mdx dystrophic mouse model after the transplantation of mdx 
mesoangioblasts genetically corrected with the DYS-HAC. In addi-
tion, the same group recently reported the differentiation in meso-
angioblast-like stem/progenitor cells from DMD patient–derived 
hiPS cells, carrying the genetic correction with the DYS-HAC.25
In this article, we aim to differentiate DMD patient–derived, geneti-
cally corrected hiPS cells into CMs with a mature phenotype and to 
assess the maintenance of the DYS-HAC during the differentiation of 
hiPS cells. In particular, we aim at investigating the correct activation, at 
HAC level, of the complex mechanisms regulating dystrophin expres-
sion, such as multiple promoter activities, which should be finely regu-
lated in a development- and tissue-specific way.
An ad hoc cardiac differentiation procedure, combining the delivery 
of cytokines with mechanical stimulation, by culturing cells on hydro-
gel with physiological stiffness, has been designed to allow full CM 
maturation. DYS-HAC–mediated dystrophin expression restoration has 
been assessed at different stages of the differentiation process.
The dystrophic CMs established in this work could potentially 
represent a valuable cell source to be used for in vitro modeling 
of DMD-associated cardiomyopathies; and, at the same time, the 
genetically corrected dystrophic CMs possess a promising thera-
peutic potential for the treatment of DMD.
ReSUlTS
Differentiation of hiPS cells toward the cardiac lineage
To obtain DMD-specific CMs, their genetic correction, and a posi-
tive control of dystrophin expression, the following hiPS cell lines 
differentiated toward the cardiac lineage were: (i) hiPS cells derived 
from a DMD patient with deletion of exons 4–43 of the muscle iso-
form Dp427m (DMD hiPS cells); (ii) DMD patient–specific hiPS cells 
genetically corrected by an HAC carrying the full-length genomic 
dystrophin sequence (DYS-HAC hiPS cells); and (iii) hiPS cells derived 
from a healthy individual (healthy hiPS cells), carrying a normal gen-
otype with a wild-type copy of the dystrophin gene.
First, DMD, DYS-HAC, and healthy hiPS cell lines were cultured and 
expanded in their undifferentiated state for up to 10 passages. During 
expansion, hiPS cell colonies maintained the expression of pluripo-
tency markers such as Oct4, Sox2, c-Myc, Tra-1-60, and Tra-1-81, 
as evaluated by immunofluorescence (see Supplementary Figure 
S1a). In addition, DYS-HAC hiPS cells were monitored for the expres-
sion of the enhanced green fluorescent protein, a marker contained 
in the DYS-HAC (see Supplementary Figure S1b). The expanded col-
onies were then used for embryoid bodies (EBs) generation.
DMD, DYS-HAC, and healthy hiPS cell–derived EBs were differenti-
ated toward the cardiac lineage through an ad hoc optimized proce-
dure. Overall outline of this procedure is shown in Figure 1a.
Remarkably, the enhanced green fluorescent protein gene, driven 
by a CAG promoter contained in the DYS-HAC,23 was expressed dur-
ing all the stages of the differentiation procedure, in DYS-HAC hiPS 
cells (Figure 1b), in DYS-HAC hiPS cell–derived EBs (Figure 1c), and 
in cultured cells after EBs adhesion (Figure 1d), indicating the stable 
maintenance of the DYS-HAC.
During the first 16 days of the differentiation procedure, EBs 
were cultured in suspension and subjected to a staged protocol, 
adapted from the one developed by Kattman et al.,26 based on the 
addition of specific cytokines—known to play a key role in cardio-
genesis during embryonic development—to the culture medium. 
This 16-day differentiation procedure resulted in a relevant per-
centage of spontaneously contracting EBs (see Supplementary 
Videos S1 and S2), ranging from a minimum of 14% for DMD 
hiPS cell–derived EBs to a maximum of 44% for healthy hiPS cell–
derived EBs (Table 1).
Our recent data demonstrated that a proper cardiac differentia-
tion requires cell–substrate interactions to promote functional and 
structural maturation of hiPS cell–derived CMs.36 For this reason, 
contracting EBs were cultured in suspension up to day 20 and 
then seeded on hydrogel substrate with a physiological stiffness 
for additional 4 days. Following adhesion, a remarkable maturation 
of CMs was observed in terms of both cytoskeletal architecture 
and cardiac markers expression (Figure 2). CMs obtained on day 
24 were characterized by a remarkable sarcomeric organization, 
as revealed by immunofluorescence of α-actinin, cardiac troponin 
T (cTnT), and F-actin, and gap junction formation, as revealed by 
immunofluorescence of connexin 43 (Figure 2a). The percentage 
of cTnT-positive CMs obtained on the overall population was ~10% 
(Table 1). The same percentage increased to 44 ± 2% when only 
contracting EBs were selected.
Expression of sarcomeric cardiac-specific proteins, in particular 
cTnT and ventricular myosin light chain, in adhered CMs, was also 
confirmed by reverse transcriptase–polymerase chain reaction 
(RT-PCR) (Figure  2b). For DMD hiPS cell–derived CMs, expression 
of ventricular myosin light chain (MLC2v), a marker of terminally 
differentiated ventricular CMs, was observed only after adhesion. 
Mesoderm- and cardiac-specific transcription factors GATA4 and 
NKX2.5 were also expressed in all conditions tested, as revealed 
by RT-PCR (Figure 2b) and immunofluorescence (Figure  2a), 
respectively.
CMs cultured in adhesion displayed both spontaneous and 
electrically induced calcium transients lasting less than 1 second, 
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typical of calcium cycling during contraction (Figure 2c), together 
with a diffuse intracellular distribution of cardiac-specific sarcoen-
doplasmic reticulum calcium-ATPase (Figure 2a), a key element of 
the calcium handling machinery needed for calcium reuptake after 
contraction.
Taken together, these results show that functionally differenti-
ated CMs were derived from DMD, DYS-HAC, and healthy hiPS cells. 
The observed differences in terms of percentage of spontaneously 
contracting EBs and cTnT-positive CMs on the overall population 
(Table 1) can be due to the intrinsic variability related to the use of 
different hiPS cell lines and the efficiency of the cardiogenic proto-
col itself.
HAC-driven expression of dystrophin sequences originally deleted 
in the DMD patient
We then focused on the genetically corrected CMs, testing the HAC-
mediated restoration of dystrophin expression.
DYS-HAC is the first vector carrying the whole dystrophin 
genomic locus, including all the associated regulatory elements.22 
This potentially allows proper activation of the complex mecha-
nism regulating dystrophin expression, for instance, the activities 
of seven different promoters driving transcription of tissue-specific 
isoforms and exon-skipping and exon-scrambling events, which are 
finely regulated in both development- and tissue-specific manner.1 
The possibility to restore dystrophin expression in a tissue-specific 
manner, following native regulation mechanisms, makes DYS-HAC 
a promising tool for the treatment of DMD also at cardiac muscle 
level.
First, dystrophin expression was analyzed on healthy, DMD, and 
genetically corrected DYS-HAC hiPS cells during the cardiac differ-
entiation procedure, by RT-PCR using specific primers designed to 
span exon–exon junctions localized inside the deleted genomic 
sequence of the DMD patient (from exon 4 to 43 of the muscle dys-
trophin isoform) (Figure 3a). mRNA from human heart and skeletal 
muscle was used as positive control.
As expected, healthy hiPS cell–derived EBs displayed dystrophin 
expression both when cultured in suspension and after adhesion, 
whereas, as expected, in DMD hiPS cell–derived EBs, no dystrophin 
expression was observed in any condition (Figure 3b). In DYS-HAC 
hiPS cell–derived EBs, dystrophin expression was restored both 
Figure 1. Differentiation of hiPS cells. (a) Schematic representation of the differentiation procedure. (b) Undifferentiated colonies of DYS-HAC hiPS cells 
cultured on murine embryonic fibroblast feeder cells. (c) EBs generated from DYS-HAC hiPS cell colonies on day 4 of the differentiation procedure. (d) 
Cultured cells 2 days after EB adhesion. Epifluorescence images show the expression of EGFP in each condition, indicating the presence of the DYS-HAC. 
BMP4, bone morphogenetic protein 4; DKK1, DICKKOPF-1; DYS-HAC, human artificial chromosome carrying the whole dystrophin genomic sequence; 
EBs, embryoid bodies; EGFP, enhanced green fluorescent protein; hiPS cells, human induced pluripotent stem cells; VEGF, vascular endothelial growth 
factor; bFGF, basic fibroblast growth factor.
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Table 1. Percentage of spontaneously contracting EBs and 
cTnT-positive cells obtained for each cell line used 
hiPS cell lines
Contracting EBs 
obtained (% ± SD): 
day16
cTnT-positive cells  
(% ± SD): day 24
DMD hiPS cells 14 ± 4 7,6 ± 0,7
DYS-HAC hiPS cells 19 ± 5 8,2 ± 1,5
Healthy hiPS cells 44 ± 2 9,8 ± 4,6
cTnT, cardiac troponin T; DMD, Duchenne muscular dystrophy; DYS-HAC, 
human artificial chromosome carrying the whole dystrophin genomic 
sequence; EBs, embryoid bodies; hiPS cells, human induced pluripotent 
stem cells; SD, standard deviation calculated on data obtained from 5 
independent analyses.
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when cultured in suspension and after adhesion. A positive result 
was obtained for each of the five exon junctions checked, distrib-
uted on the whole deleted genomic region.
HAC-driven expression of multiple dystrophin isoforms
In vivo, CMs are known to express the full-length muscle dystro-
phin isoform (Dp427m), together with other isoforms, such as the 
Dp260 (ref. 27) and Dp71, the smallest but multifunctional prod-
uct of the DMD gene expressed in many tissues, including cardiac 
muscle. Dp71 has been shown to contribute to the proper cluster-
ing and anchoring of structural and signaling proteins to the plasma 
membrane and of nuclear envelope proteins to the inner nuclear 
membrane.28
The expression of different dystrophin isoforms such as Dp427m, 
Dp260, Dp140, and Dp71 was analyzed by RT-PCR during the cardiac 
differentiation procedure on healthy, DMD, and DYS-HAC hiPS cells 
(Figure 4a). mRNA from human tissues was used as positive control.
As expected, healthy hiPS cell–derived EBs (both in suspension 
and after adhesion) displayed the expression of all the four differ-
ent dystrophin isoforms.  The expression of isoform Dp140 indicates 
other cell types are present besides CM.29 In DMD hiPS cell–derived 
EBs, the expression of the Dp260 isoform, the promoter of which 
stands within the large genomic deletion (exons 4–43), was not 
observed, whereas isoforms Dp140 and Dp71 were still detect-
able as their promoters are downstream of the deleted area (intron 
44 and intron 62, respectively). The amplicon relative to isoform 
Dp427m is still present, as the primers specific for this isoform are 
designed on the first transcribed exons (exons 1–3), upstream of the 
deletion, testifying a proper initiation of dystrophin transcription. 
On DYS-HAC hiPS cell–derived EBs (both in suspension and after 
adhesion), expression of all isoforms can be observed, notably with 
the restoration of Dp260 isoform transcript.
To assess the efficiency of HAC-driven recovery of dystrophin 
mRNA levels, we performed RT-PCR experiments targeted at the 
isoforms expressed in the cardiac tissue (Figure 4b). A set of prim-
ers targeting exons 25–26 identifying all Dp427 isoforms was 
used in addition to the Dp427m-specific one to assess the rela-
tive expression of Dp427 transcripts inside the deleted genomic 
region. Confirming the previous results of the RT-PCR, DMD hiPS 
cell–derived EBs did not display at all the expression of transcripts 
from inside the deleted genomic region, both in regard to Dp427 
isoforms, the transcription of which is truncated after exon 4, and 
in regard to Dp260 isoform, the transcription of which cannot be 
initiated. The expression of the truncated Dp427m isoform and the 
short Dp71 isoform was variable among the different experiments, 
not reaching statistical significance (n = 3). Differentiated healthy 
and DYS-HAC hiPS cell–derived CMs displayed similar amounts of 
all transcripts tested, highlighting the proper function of the HAC 
in driving and regulating the transcription of different dystrophin 
isoforms.
Figure 2. Characterization of hiPS cell–derived CMs. (a) Immunofluorescence of α-actinin; cardiac troponin T (cTnT) and F-actin; connexin 43 
(Cnx43); sarcoendoplasmic reticulum calcium-ATPase (SERCA2a); and GATA4 in adhered CMs on day 24 of the differentiation procedure. Nuclei are 
counterstained with DAPI. (b) RT-PCR shows the expression of NKX2.5, cTnT, and MLC2v in EBs obtained from DMD, healthy, and DYS-HAC hiPS cells 
cultured in suspension (on day 20) and on the EB-derived adhered cells on day 24 of the differentiation procedure. (c) Typical calcium transients 
displayed by hiPS cell–derived CMs on day 24 of the differentiation procedure. The histogram reports quantitative evaluation of calcium reuptake rate 
by the half-life of calcium decay and the calcium release phase as the time to peak. Data are presented as SD. CMs, cardiomyocytes; DAPI, 4′,6-diamidino-
2-phenylindole; DMD, Duchenne muscular dystrophy; DYS-HAC, human artificial chromosome carrying the whole dystrophin genomic sequence; hiPS 
cells, human induced pluripotent stem cells; MLC2v, ventricular myosin light chain; RT-PCR, reverse transcriptase–polymerase chain reaction.
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Taken together, these analyses on mRNA transcripts show that, 
during the cardiac differentiation protocol, dystrophin expression 
is correctly restored by the DYS-HAC and multiple dystrophin iso-
forms are expressed.
HAC-mediated restoration of dystrophin protein expression and 
correct subcellular localization
In vivo, in physiological conditions, dystrophin is a key structural 
protein creating a bridge across the sarcolemma, which provides 
a flexible connection between the basal lamina of the extracellular 
matrix and the inner cytoskeleton. For this  important role, dystro-
phin should be correctly folded and localized under the plasma 
membrane of skeletal and cardiac muscle cells.
For this reason, we verified the proper restoration of dystrophin 
expression at protein level and its subcellular localization by immu-
nofluorescence and confocal microscopy. Analyses were performed 
4 days after EB adhesion on substrate with a physiological stiffness 
of 15 kPa (Figure 5a).
DYS-HAC hiPS cell–derived EBs displayed a clear dystrophin 
expression at membrane localization, drawing the boundaries of 
Figure 3. HAC-driven expression of dystrophin sequences originally deleted in DMD patients. (a) The genomic organization of the dystrophin gene: the 
gray vertical bars represent the exons; the green arrows indicate the promoters driving the expression of the different dystrophin isoforms within the 
gene1,2; primer pairs used to amplify exon–exon junctions inside the deleted region are indicated by red arrowheads, and those used to amplify specific 
isoforms are indicated by blue arrowheads. Exon number here reported refers to the muscle dystrophin isoform Dp427m. (b) RT-PCR of specific dystrophin 
sequences localized inside the patient with deletion of exons (Ex) 4–43. Primers were constructed to spam five different exon–exon junctions (Ex. J.). cDNA 
from human heart and skeletal muscle was used as positive control. Analyses were performed at three different stages of the differentiation process: 
undifferentiated colonies, differentiated EBs cultured in suspension (day 20), and adhered cells (day 24), for each hiPS cell lines (DMD, healthy, and DYS-HAC 
hiPS cells). cDNA from human tissues was used as positive control. cDNA, complementary DNA; DMD, Duchenne muscular dystrophy; DYS-HAC, human 
artificial chromosome carrying the whole dystrophin genomic sequence; EBs, embryoid bodies; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 
HAC, human artificial chromosome; hiPS cells, human induced pluripotent stem cells; RT-PCR, reverse transcriptase–polymerase chain reaction.
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cTnT-positive CMs. A similar dystrophin staining was observed in 
healthy hiPS cell–derived EBs. On the other hand, as expected, in 
DMD hiPS cell–derived EBs, no dystrophin staining was observed. 
These results were confirmed by western blot analysis, in which 
full-length dystrophin was not observed in DMD hiPS cell–
derived CMs, whereas its expression was perfectly restored in 
CMs  corrected with the DYS-HAC (Figure 5b). Although much less 
abundant, other dystrophin isoforms were also detectable in the 
DYS-HAC–corrected cells (see Supplementary Figure S2).
These results demonstrate that the DYS-HAC restores the expression 
of dystrophin at protein level, which can correctly localize at membrane 
level in genetically corrected, hiPS cell–derived CMs.
DISCUSSION
The derivation of genetically corrected, patient-specific hiPS cells 
has been recently shown to be a promising strategy for modeling 
genetic diseases. In particular, An et al.30 reported the derivation of 
hiPS cells from Huntington’s disease patients’ fibroblasts that were 
genetically corrected by an homologous recombination approach 
and differentiated into DARPP-32–positive neurons. Tedesco et al.25 
reprogrammed fibroblasts and myoblasts from limb-girdle muscular 
dystrophy patients in hiPS cells and developed a protocol for the der-
ivation of mesoangioblast-like cells that were genetically corrected 
in vitro with a lentiviral vector carrying the human α-sarcoglycan 
gene. The huge potential of hiPS cell technology has also been 
demonstrated in modeling human cardiovascular diseases. Some 
pioneering proof-of-concept studies on patients with inherited 
arrhythmogenic diseases, most notably different subtypes of long 
QT syndrome, demonstrated how hiPS cell–derived cardiac cells 
reproduce the clinical phenotype “in the petri dish.”14,31
In this work we derived, for the first time to our knowledge, human 
CMs (hCMs) from DMD patient–specific hiPS cells and genetically 
corrected hCMs from DYS-HAC–containing hiPS cells.
Different procedures for the cardiac differentiation of pluripo-
tent stem cells have been reported in literature, mainly reproduc-
ing in vitro the processes of embryonic development through the 
stimulation with soluble cytokines, driving pluripotent stem cells 
toward early mesoderm specification until the derivation of cardiac 
progenitor cells.26,32,33 However, the major drawback of their applica-
tion, both in vitro and in vivo, is their immature phenotype.
To study the restoration of dystrophin expression and its correct 
localization in cardiac cells, the derivation of hCMs characterized by 
a functionally and structurally mature phenotype is of paramount 
importance.
We developed an ad hoc optimized differentiation proce-
dure integrating a cytokine-based EBs differentiation with a 
Figure 4.  HAC-driven expression of multiple dystrophin isoforms. (a) RT-PCR of dystrophin isoforms Dp427m, Dp260, Dp140, and Dp71 at three 
different stages of the differentiation process: undifferentiated colonies, differentiated EBs cultured in suspension (day 20), and adhered cells 
(day 24), for each hiPS cell lines (DMD, healthy, and DYS-HAC hiPS cells). cDNA from human tissues was used as positive control. (b) Real-
time PCR  for dystrophin isoforms present in cardiac tissue. Muscle-specific Dp427m is double checked with Dp427m-specific primer set 
spanning exons 1–3 and an all Dp427 isoform-specific primer set spanning exons 25–26. Data are presented as mean ± SD. cDNA, complementary 
DNA; DYS-HAC, human artificial chromosome carrying the whole dystrophin genomic sequence; EBs, embryoid bodies; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; HAC, human artificial chromosome; hiPS cells, human induced pluripotent stem cells; RT-PCR, reverse transcriptase–
polymerase chain reaction; DMD, Duchenne muscular dystrophy.
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subsequent step of adhesion-dependent maturation. Increasing 
evidence demonstrate that adhesion and substrate sensing are 
key requirements for the process of muscle cell functional dif-
ferentiation. In our previous work, we have shown that the devel-
opment of sarcomeric structures of human striated muscles is 
influenced by the substrate on which the cells are cultured.34 
Furthermore, in our group, it has been recently demonstrated 
that adhesion on substrate with a physiological stiffness pro-
motes functional maturation of hCMs, allowing a shortening of 
calcium transients.36
Using the procedure developed, we derived hCMs present-
ing expression of cardiac-specific markers, a defined sarcomeric 
organization and calcium transients lasting less than 1 second. 
In these conditions, dystrophin has been observed to correctly 
localize at membrane level on both healthy and genetically cor-
rected hCMs.
Certain variability has been observed in the expression of cardiac 
muscle markers along the differentiation process, for the different 
hiPS cell lines. This could be explained since, as widely reported in 
literature, hiPS cell lines derived from different cells and different 
clones can have a different ability to differentiate toward the car-
diac lineage. In addition, it has been recently demonstrated that 
in vitro cultured DMD skeletal muscle cells display a delay in the 
appearance of typical myogenic markers.35 Similarly, we observed 
a delay in the expression of the late cardiac differentiation marker 
ventricular myosin light chain in DMD-derived cardiac cells, com-
pared with the healthy and genetically corrected (DYS-HAC) ones. 
Further analyses could be performed to specifically address this 
issue in cardiac muscle.
hiPS cell–derived CMs represent a unique platform for testing 
in vitro the efficiency of the DYS-HAC in restoring a proper dystro-
phin expression at cardiac level, in a patient-specific manner.
DYS-HAC is a potential tool for use in DMD gene correction, and 
its ability to properly restore dystrophin expression on differenti-
ated human cells has been recently reported.25 However, its effi-
ciency in restoring different isoforms’ expression on differentiated 
hCMs has not been extensively investigated so far. For the first time, 
we demonstrated that DYS-HAC (i) does not hinder and is stably 
maintained during cardiac differentiation of hiPS cells; (ii) allows 
a proper dystrophin expression restoration during the cardiac dif-
ferentiation procedure of hiPS cells (in particular, the expression of 
specific sequences deleted in the patient was observed); (iii) drives 
the transcription of multiple dystrophin isoforms in CMs at similar 
expression levels compared with healthy hiPS cell–derived CMs, in 
particular, the full-length muscle isoform Dp427m and the cardiac 
isoform Dp260, which are not expressed in the DMD patient with 
deletion of exons 4–43; and (iv) allows the recovery of full-length 
dystrophin protein that localizes properly at the cell membrane. 
These results highlight DYS-HAC as a potential tool for use in gene 
correction of DMD patient cells.
Finally, the coupling of DMD CMs with specific technologies for 
testing cardiac functionality, such as measurement of force genera-
tion or performance under stressed condition, will provide a unique 
platform for studying in vitro the pathogenesis of DMD-associated 
cardiac disease and its correction.
MATeRIAlS AND MeTHODS
hiPS cell culturing and cardiac differentiation
hiPS cells, obtained as previously reported,23 were cultured on a feeder layer 
of mitomycin-C–inactivated murine embryonic fibroblasts. Composition of 
the culture medium was as follows: Dulbecco's modified Eagle medium/
F12 (Life Technologies, Carlsbad, CA) containing 20% knockout serum (Life 
Technologies), 2 mmol/l of l-glutamine (Life Technologies), 0.1 mmol/l of 
nonessential amino acids (Life Technologies), 0.1 mmol/l of 2-mercapto-
ethanol (Life Technologies), 50 units and 50 mg/ml of penicillin and strep-
tomycin (Life Technologies), and 4 ng/ml of basic fibroblast growth factor 
(Peprotech, Rocky Hill, NJ).
To maintain the pluripotent state for a high number of passages and avoid 
chromosomal aberrations, the colonies were passed as described below—
usually once a week. hiPS cells were washed with phosphate-buffered 
saline (PBS) and treated with 1 ml of Collagenase, trypsin, knockout serum 
solution for 30 seconds. Collagenase, trypsin, knockout serum solution was 
prepared as follows: 5 ml of 2.5% trypsin (Life Technologies), 5 ml of 1 mg/ml 
collagenase IV (Sigma-Aldrich, St Louis, MO), 0.5 ml of 0.1 mol/l CaCl2 (Sigma-
Aldrich), and 10 ml of knockout serum were all added to 30 ml of distilled 
water. The mechanical separation of colonies was performed using a cutting 
pipette through a stereomicroscope. The selected undifferentiated pieces 
Figure 5.  HAC-mediated restoration of dystrophin protein expression and correct subcellular localization. (a) Confocal microscopic analysis of dystrophin 
and cardiac troponin T expression on CMs obtained on day 24 of the differentiation procedure from DMD, healthy, and DYS-HAC hiPS cells. Nuclei are 
counterstained with DAPI. (b) Western blot analysis for dystrophin isoforms with a polyclonal antibody and for cardiac marker troponin T detected in two 
isoforms in the samples from human hiPS cell–derived cardiomyocytes. CMs, cardiomyocytes; DAPI, 4′,6-diamidino-2-phenylindole; DMD, Duchenne 
muscular dystrophy; DYS-HAC, human artificial chromosome carrying the whole dystrophin genomic sequence; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; HAC, human artificial chromosome; hiPS cells, human induced pluripotent stem cells.
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were then replated for expansion onto dishes containing fresh murine 
embryonic fibroblast feeders or moved to ultralow adhesion plates to be 
cultured in suspension for EB generation.
The obtained EBs were differentiated in suspension using a pro-
tocol adapted from Kattman et al.26 Briefly, for EB formation, the 
detached and separated colonies were maintained for 24 hours in basal 
medium (StemPRO-34; Life Technologies), 2 mmol/l of l-glutamine 
(Life Technologies), 150 µg/ml of transferrin (Roche, Basel, Switzerland), 
50 µg/ml of ascorbic acid (Sigma-Aldrich), 0.4 mmol/l of monothioglyc-
erol (Sigma-Aldrich), 50 units and 50 mg/ml of penicillin and strepto-
mycin (Life Technologies) supplemented with 10 ng/ml of human bone 
 morphogenetic protein 4 (R&D Systems, Minneapolis, MN). From day 1 to 
day 4, EBs were cultured in basal medium with 10 ng/ml of human bone 
morphogenetic protein 4, 5 ng/ml of human basic fibroblast growth fac-
tor (R&D), and 6 ng/ml of hActivin A (R&D). From day 4 to day 8, the EB cul-
ture medium consisted of basal medium and 10 ng/ml of human vascular 
endothelial growth factor (R&D) and 150 ng/ml of human DICKKOPF-1 
(R&D). Finally, from day 8 to day 14, the EB culture medium consisted of 
basal medium and 10 ng/ml of human vascular endothelial growth factor 
and 5 ng/ml of human basic fibroblast growth factor. Cultures were main-
tained in a 5% CO2, 5% O2, and 90% N2 environment for the first 16 days 
and then transferred to a 5% CO2 air environment.
The obtained EBs were maintained in suspension using the last medium 
described until day 20 and then seeded on hydrogel substrates with a physi-
ological stiffness of 15 kPa (prepared as previously described)34,36,37, function-
alized with 100 µg/ml of laminin (Becton Dickinson, Franklin Lakes, NJ), and 
cultured in these conditions for additional 4 days.
Immunofluorescence
A standard immunohistochemistry protocol was used. Briefly, cells were 
fixed with PBS containing 2% paraformaldehyde (Sigma-Aldrich) for 7 min-
utes, permeabilized with PBS containing 0.5% Triton X-100 (Sigma-Aldrich), 
and blocked in PBS containing 2% horse serum for 45 minutes, at room 
temperature. Primary antibodies were applied for 1 hour at 37 °C. Cells were 
washed in PBS (Life Technologies) and incubated with fluorescence-conju-
gated secondary antibodies against mouse, rabbit, or goat, depending on 
primary antibody used, for 45 minutes at 37 °C. Finally, nuclei were counter-
stained with 4′,6-diamidino-2-phenylindole (Sigma-Aldrich), and samples 
were mounted with Elvanol (Sigma-Aldrich) and viewed under Leica TCS SP5 
fluorescence confocal microscope (Leica Microsystems, Wetzlar, Germany). 
Primary antibodies used were the following: mouse monoclonal anti-cTnT 
(Thermo Scientific, Waltham, MA; #MS-295-P; 1:100 dilution), mouse mono-
clonal anti-α-actinin (Sigma-Aldrich; #A7811; 1:100 dilution), rabbit polyclonal 
anti-dystrophin (Abcam, Cambridge, UK; #ab15277; 1:200 dilution), mouse 
monoclonal anti-Cx43 (Millipore; #MAB3067; 1:100 dilution), goat polyclonal 
anti-SERCA2a (Santa Cruz; #SC 8094; 1:200 dilution), and goat polyclonal anti-
GATA4 (Santa Cruz; #SC 1237; 1:200 dilution). Secondary antibodies used were 
the following: goat anti-mouse (Life Technologies; #A11005 and #A11001; 
1:200 dilution), goat anti-rabbit (Life Technologies; #A11012 and A1108; 1:200 
dilution), and donkey anti-goat (Jackson ImmunoLab, West Grove, PA; #705-
165-003; 1:300 dilution). All antibodies were diluted in 3% bovine serum albu-
min (Sigma-Aldrich).
Calcium measurements
Confocal calcium measurements were performed as previously reported in 
Martewicz et al.38 Briefly, CMs were loaded in serum-free Dulbecco’s modi-
fied Eagle medium containing 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES) 25 mmol/l (Life Technologies) and supplemented 
with 2,5 mmol/l of fluorescent calcium dye Fluo-4 AM (Life Technologies) 
for 20 minutes at 37 °C in the presence of 2 mmol/l of Pluronic F-127 
(Life Technologies) and 20 mmol/l of sulfinpyrazone (Sigma-Aldrich), then 
incubated for additional 10 minutes at 37 °C without Fluo-4 AM, and added 
with 0.2 mmol/l of di-8-ANEPPS (Life Technologies). Cell dynamics were 
obtained in recording solution: NaCl, 125 mmol/l; KCl, 5 mmol/l; Na3PO4, 
1 mmol/l; MgSO4, 1 mmol/l; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid, 20 mmol/l; CaCl2, 2 mmol/l; and glucose, 5.5 mmol/l, to pH 7.4 with 
NaOH. Line scans were acquired with a Leica TCS SP5 fluorescence confo-
cal microscope using a 63× oil immersion objective, with 488-nm Ar laser 
line as an excitation source and 400-Hz acquisition frequency. Line scans 
were then analyzed using ImageJ software (version number 1.46; National 
Institutes of Health, Bethesda, MD) to obtain calcium transient profile. For 
evaluating the calcium reuptake rate after contraction, the half-life of the 
calcium decay was considered. Half-life of the calcium decay was calculated 
by fitting a first-order exponential decay to the calcium reuptake phase 
of the calcium transient profile. For the calcium release phase, the time to 
peak value was calculated considering the time from baseline to a mini-
mum of the second derivative of the calcium transient. All numerical data 
were manipulated with Origin 8.1 software (Origin Lab, Northampton, MA).
Reverse transcriptase–polymerase chain reaction
Total RNA from hiPS cell colonies and differentiated EBs was purified with 
RNeasy Mini Kit (Qiagen, Venlo, Netherlands), in accordance with the manu-
facturer’s instructions, or with TRIzol reagent (Life Technologies) and treated 
using a Turbo DNA-free kit (Life Technologies) to remove genomic DNA 
contamination. For the cardiac marker analyses, first-strand complementary 
DNA (cDNA) synthesis was performed using an oligo-(dT)20 primer and 
the cDNA Reverse Transcription Kit (Life Technologies). PCR was performed 
with cDNA using AmpliTaq Gold (Life Technologies). Amplifications were 
performed with an annealing temperature of 55 or 58 °C for 30–35 cycles. 
For the dystrophin isoform analyses, cDNA retrotranscription was carried 
out with High Capacity cDNA Reverse Transcription Kit (Life Technologies), 
followed by RT-PCR using Platinum Taq Polymerase (Life Technologies) 
with annealing temperature of 60 °C for 35 cycles. All the amplicons were 
resolved by electrophoresis on a 2% agarose gel, followed by staining with 
SYBR Safe Gel. Primer sequences are given in Table 2.
Real-time PCR
Real-time PCR on cDNA retrotranscribed with High Capacity cDNA Reverse 
Transcription Kit was carried out with Power SYBR Green PCR Master Mix (Life 
Technologies) in a 7000 System thermal cycler platform (Life Technologies). 
Annealing temperature for all primer sets was 60 °C (sequences reported in 
Table 2). Relative amount of transcripts was calculated with Pfaffl method 
relative to healthy hiPS cell–derived EB expression levels. Amplification effi-
ciency for all primer sets was >1.9.
Table 2. Primer sequences 
Forward primer Reverse primer
Dystrophin isoform Dp427m (exons 1–3) TCGCTGCCTTGATATACACTTTTCA GGTTCTCAATATGCTGCTTCCCA
Dystrophin isoform Dp260 AGGAAGCTGCGAAATCTGTCTTAC GGCAGACTGGATGCTCTGTTCA
Dystrophin isoform Dp140 ACCGAAAGAGGTTTTTGCACACC ACTGGCATCTGTTTTTGAGGATTGC
Dystrophin isoform Dp71 CATGAGGGAACAGCTCAAAGGC CAGTCTTCGGAGTTTCATGGCA
Dystrophin exon junctions 3–4 CCTGACAGGGCAAAAACTGCCAA TGTGTGGCTGACTGCTGGCAA
Dystrophin exon junctions 9–10 CGGAGCCCATTTCCTTCACAGCATT CCGGCCCTGATGGGCTGTCA
Dystrophin exon junction 22–23 GACTCGGGGAATTGCAGGCTT GGGCAGGCCATTCCTCCTTCA
Dystrophin exon junction 25–26 GGCCTGCCCTTGGGGATTCA TCTGGCATAGACCTGTTGGCACA
Dystrophin exon junction 34–35 TGCCTGGGGAAAGGCTACTCA GCAGTGGTCACCGCGGTTTG
NKX2.5 GCGATTATGCAGCGTGCAATGAGT AACATAAATACGGGTGGGTGCGTG
cTnT TTCACCAAAGATCTGCTCCTCGCT TTATTACTGGTGTGGAGTGGGTGTGG
MLC2v ACATCATCACCCACGGAGAAGAGA ATTGGAACATGGCCTCTGGATGGA
GAPDH RT-PCR CCCCTTCATTGACCTCAACTACA TTGCTGATGATCTTGAGGCTGT
GAPDH real-time PCR GAAGGTGAAGGTCGGAGTCAAC CAGAGTTAAAAGCAGCCCTGGT
cTnT, cardiac troponin T; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MLC2v, ventricular myosin light chain; RT-PCR, reverse transcriptase–polymerase 
chain reaction.
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Western blot analyses
Detection of dystrophin (antibody 1:500; overnight + 4 °C; Abcam; #ab15277), 
cTnT (antibody 1:500; 60 minutes at room temperature; Thermoscientific 
#MS-295-P), and glyceraldehyde 3-phosphate dehydrogenase (antibody 
1:2,000; 60 minutes at room temperature; Abcam; #ab8245) was carried out 
after protein lysates were resolved in a NuPAGE 3–8% Tris-acetate polyacryl-
amide gel (Life Technologies) and transferred for 6 hours at 4°C on a poly-
vinylidene difluoride membrane (Life Technologies) with a BioRad cassette. 
Detection was performed with Novex ECL Kit (Life Technologies). Anti-rabbit 
(Life Technologies) and anti-mouse (BioRad) secondary horseradish peroxi-
dase–conjugated antibodies were used.
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